Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03588936 · ClinicalTrials.gov registry record · Phase 1
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03588936: Clinical Trial Phase 1 study, sponsored by Medical College of Wisconsin.
NCT03588936 is a Phase 1 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03588936, a Phase 1 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6 (IL-6) inhibition in participants with relapsed disease post-allogeneic transplant.
Primary Outcome
Determine the safety and the maximum tolerated dose among two candidate doses of nivolumab in combination with tocilizumab for treatment of relapsed hematological malignancy post-allogeneic transplant. Maximum-tolerated dose is based on the determination of dose-limiting toxicities.
Interventions
- DRUG Tocilizumab
- DRUG Nivolumab (.25 mg/kg)
- DRUG Nivolumab (.5 mg/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 1 |
Why NCT03588936 stopped before completion
NCT03588936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Tocilizumab is the first listed.
NCT03588936 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03588936 about?
NCT03588936 is a clinical study titled "Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant". This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6 (IL-6) inhibition in participants with relapsed disease post-allogeneic transplant.
What is the current status of trial NCT03588936?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2018-09-14. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03588936?
The interventions under investigation include: Tocilizumab (DRUG), Nivolumab (.25 mg/kg) (DRUG), Nivolumab (.5 mg/kg) (DRUG).
Who is sponsoring clinical trial NCT03588936?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03588936's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI